Amgen Inc Liquidation Value

AMGN Biotechnology

Cash & Equivalents

$12.04B
As of 2026-03-31
Current Price: $326.31 (as of 2026-05-18)

Key Metrics

Cash Liquidation Value

Cash minus Total Obligations
Cash: $12.04B
Total Obligations: -$76.84B
$-64.80B
Per share: $-120.07
Period: 2026-03-31
incomplete 2 components missing — treated as $0 in formula. Why?
  • Finance Lease Liability: not reported in this period (annual-only)
  • Operating Lease Liability: not reported in this period (annual-only)

Liquid Liquidation Value

Cash + AR minus Total Obligations
Cash: $12.04B
AR: $9.14B
Total Obligations: -$76.84B
$-55.66B
Per share: $-103.14
Period: 2026-03-31
incomplete 2 components missing — treated as $0 in formula. Why?
  • Finance Lease Liability: not reported in this period (annual-only)
  • Operating Lease Liability: not reported in this period (annual-only)

Operating Liquidation Value

Cash + AR + Inventory minus Total Obligations
Cash: $12.04B
AR: $9.14B
Inventory: $6.19B
Total Obligations: -$76.84B
$-49.48B
Per share: $-91.68
Period: 2026-03-31
incomplete 2 components missing — treated as $0 in formula. Why?
  • Finance Lease Liability: not reported in this period (annual-only)
  • Operating Lease Liability: not reported in this period (annual-only)

Build your own liquidation scenario

Adjust asset discounts and liability assumptions to see how assumptions affect the numbers.

Open Calculator →

Liquidation Ladder

MetricTotalPer Share
Cash Liquidation Value$-64.80B$-120.07
Liquid Liquidation Value$-55.66B$-103.14
Operating Liquidation Value$-49.48B$-91.68

Key Components (as of 2026-03-31)

Data as of 2026-03-31 from 10-Q filed 2026-05-01. View on SEC EDGAR →

Cash & Equivalents$12.04B
Accounts Receivable$9.14B
Inventory$6.19B
Current Liabilities$24.95B
Long-term Debt (?)$51.89B
Op. Lease Liability (?)N/A
Finance Lease (?)N/A
Shares Outstanding539.7M

Explore all 118 XBRL tags and build your own scenario → Open Calculator

Historical

PeriodCashARInventoryAPCurr LiabLT DebtOp LeaseFin Lease
2026-03-31$12.04B$9.14B$6.19B$2.94B$24.95B$51.89BN/AN/A
2025-12-31$9.13B$9.57B$6.22B$2.37B$25.49B$50.01B$696.00MN/A
2025-09-30$9.45B$8.49B$6.35B$2.84B$21.79B$52.43BN/AN/A

Comments

SEC Filings

PeriodFormFiledLink
2026-03-31 10-Q 2026-05-01 View
2025-12-31 10-K 2026-02-13 View
2025-09-30 10-Q 2025-11-05 View
2025-06-30 10-Q 2025-08-06 View
2025-03-31 10-Q 2025-05-02 View
2024-12-31 10-K 2025-02-14 View
2024-09-30 10-Q 2024-10-31 View
2024-06-30 10-Q 2024-08-07 View

AI Insights

AI Insight·Generated 2026-05-04

AMGEN INC (AMGN) presents a deeply negative liquidation posture as of March 31, 2026. The MFFAIS-computed cash liquidation value of approximately negative $64.8B and liquid liquidation value of approximately negative $55.7B reflect the structural reality of a balance sheet dominated by intangible assets and a heavily loaded long-term debt stack. Under the liquidation lens, total assets of $92.5B are subject to severe haircuts. Applying standard recovery rates: cash and equivalents of $12.0B recover at par; accounts receivable of $9.1B recover at roughly $8.2B (90%); inventory of $6.2B recovers at approximately $3.7B (60%); PP&E net of $8.2B recovers at roughly $4.9B (60% of gross carrying value after accumulated depreciation of $9.3B is already embedded); goodwill of $18.7B and finite-lived intangibles net of $20.7B receive zero recovery under a liquidation framework. Total adjusted asset recovery is therefore concentrated in liquid and tangible assets, estimated in the $35-40B range before friction costs. Against this, liabilities are carried at face value: current liabilities of $25.0B (inclusive of $5.4B current debt and $16.6B accrued liabilities), long-term debt of $51.9B, and additional noncurrent liabilities including $2.8B of uncertain tax positions and $2.4B of other long-term liabilities. Total face-value obligations approximate $83B, producing a substantial negative recovery to equity consistent with the computed LLV. A material development this period is the issuance of $4.0B of new long-term notes in Q1 2026 at coupons of 4.20% to 5.65%, offset by repayment of $0.8B and extinguishment of $0.3B, resulting in a net increase in gross debt from approximately $54.6B to approximately $57.3B. This further widens the liability stack relative to tangible asset recovery. Cash increased $2.9B to $12.0B, primarily from net debt proceeds of $3.2B and operating cash flow of $2.2B less dividends of $1.4B and capex of $0.7B. The IRS tax contingency ($3.6B + $5.1B in proposed deficiencies for 2010-2015, partially offset by $3.1B of prior repatriation taxes paid) represents an unaccrued contingent liability that, if crystallized, would further impair recovery. No prior filing was available for QoQ comparison.

Flags

Loading flags...

AI Insight Discussion

Loading...

Community Notes

Loading notes...

Questions

Loading questions...